Gonadotropin-releasing hormone peptide · Fact sheet
Gonadorelin
Also known as GnRH · Gonadotropin-releasing hormone · Factrel · Lutrepulse
Gonadorelin is synthetic gonadotropin-releasing hormone, which stimulates pituitary LH and FSH. Historical U.S. human products are discontinued from marketing; specialized pulsatile-pump research does not establish an interchangeable occasional-injection fertility regimen.
What is Gonadorelin?
GnRH signaling depends on exposure pattern. Pulsatile delivery and prolonged continuous receptor stimulation are different interventions.
Human gonadorelin medicines and veterinary products must be distinguished by product and indication.
Benefits & claims
Interest centers on reproductive endocrinology, diagnostic testing and selected hypogonadotropic disorders. A rise in LH does not by itself establish fertility or symptom improvement.
What the evidence supports
- The pump study found earlier detected spermatogenesis, but eventual rates were not significantly different between the treatment groups.
- Treatment groups were small and not randomized, leaving selection and prior-treatment confounding.
- A specialized pump protocol cannot validate a differently timed product or routine testosterone-adjunct claim.
Research areas
- Congenital hypogonadotropic hypogonadism
- Pituitary reproductive signaling
- Historical diagnostic and reproductive uses
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Gonadorelin. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- GnRH signaling depends on exposure pattern. Pulsatile delivery and prolonged continuous receptor stimulation are different interventions.
Formulation differences
- The historical U.S. products were different salts and delivery products. Veterinary approval does not authorize human use.
- Published pump research does not establish an equivalent intermittent regimen.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Comparability of current nonstandard products to historical medicines
- Fertility outcomes beyond sperm detection
- Long-term safety across delivery patterns
Side effects & risks
- The pump study reported local allergic skin reactions.
- Hormonal and reproductive effects depend on underlying pituitary function, exposure pattern and co-treatment; small trials cannot establish broad safety.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceA small nonrandomized congenital-hypogonadotropic-hypogonadism study compared pulsatile pump therapy with gonadotropins. Another small study measured bone and metabolic changes; neither establishes general wellness use.
Studies
28 men; nonrandomized pulsatile-pump versus gonadotropin comparison.
22 young men with hypogonadotropic hypogonadism; bone/metabolic study.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
FDA application records list all human Factrel and Lutrepulse products as discontinued from marketing. Marketing discontinuation does not by itself establish withdrawal of approval, a safety reason or absence of every research use.
Historical U.S. products discontinued from marketing
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- FDA application records: gonadorelin products
- The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men.
- Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism.
Open questions
- Comparability of current nonstandard products to historical medicines
- Fertility outcomes beyond sperm detection
- Long-term safety across delivery patterns
Summary
A specialized pump protocol cannot validate a differently timed product or routine testosterone-adjunct claim.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA application records: gonadorelin products
Exact ingredient application records: Factrel NDA018123 and Lutrepulse NDA019687 products are listed as discontinued from marketing.
- pubmedThe Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men.
28 men; nonrandomized pulsatile-pump versus gonadotropin comparison.
- pubmedChanges in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism.
22 young men with hypogonadotropic hypogonadism; bone/metabolic study.